• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

177Lu-PSMA radioligand therapy for isolated bilateral adrenal metastases from prostate cancer.

作者信息

Perrone Elisabetta, Ghai Kriti, Eismant Aleksandr, Konz Kornelia, Baum Richard P

机构信息

CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany; Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, Italy.

CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany.

出版信息

Acta Oncol. 2024 Jul 5;63:557-562. doi: 10.2340/1651-226X.2024.40017.

DOI:10.2340/1651-226X.2024.40017
PMID:38967321
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11332551/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5048/11332551/e7d8f8a8257c/AO-63-40017-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5048/11332551/831e869dda9e/AO-63-40017-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5048/11332551/ad725156b34c/AO-63-40017-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5048/11332551/e9efaa68c084/AO-63-40017-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5048/11332551/e7d8f8a8257c/AO-63-40017-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5048/11332551/831e869dda9e/AO-63-40017-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5048/11332551/ad725156b34c/AO-63-40017-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5048/11332551/e9efaa68c084/AO-63-40017-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5048/11332551/e7d8f8a8257c/AO-63-40017-g004.jpg

相似文献

1
177Lu-PSMA radioligand therapy for isolated bilateral adrenal metastases from prostate cancer.177镥-前列腺特异性膜抗原放射性配体疗法治疗前列腺癌孤立性双侧肾上腺转移瘤
Acta Oncol. 2024 Jul 5;63:557-562. doi: 10.2340/1651-226X.2024.40017.
2
Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot.用于转移性前列腺癌的镥-PSMA-617：找准靶点
Lancet. 2024 Sep 28;404(10459):1174-1176. doi: 10.1016/S0140-6736(24)01919-6. Epub 2024 Sep 15.
3
A step closer to the use of [Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer.离在转移性激素敏感性前列腺癌中使用[镥]镥-PSMA-617又近了一步。
Lancet Oncol. 2024 Oct;25(10):1246-1247. doi: 10.1016/S1470-2045(24)00506-0.
4
A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?携镥-177 PSMA 同行：我们从基础研究到临床应用已走多远？
Cancer Invest. 2020 Sep;38(8-9):486-492. doi: 10.1080/07357907.2020.1811301. Epub 2020 Sep 14.
5
Preparation of Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House.医院放射性药物制备：使用内部开发的单瓶冻干 PSMA-617 试剂盒方便地配制临床剂量。
Biomed Res Int. 2021 Nov 20;2021:1555712. doi: 10.1155/2021/1555712. eCollection 2021.
6
Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review.镥-177-PSMA-617 前列腺特异性膜抗原靶向放射性配体治疗中的剂量学：系统评价。
Nucl Med Commun. 2022 Apr 1;43(4):369-377. doi: 10.1097/MNM.0000000000001535.
7
Value of post-therapy Lu-PSMA images for accurate interpretation of therapy response with Ga-PSMA PET/CT.治疗后镥-PSMA图像对于准确解读镓-PSMA PET/CT治疗反应的价值。
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Mar-Apr;37(2):114-117. doi: 10.1016/j.remn.2017.05.004. Epub 2017 Jul 24.
8
Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy.在接受[177Lu]Lu-PSMA-617放射性配体治疗的mCRPC患者的[68Ga]Ga-PSMA-11 PET/CT检查中偶然发现胰腺腺癌。
Nuklearmedizin. 2024 Jun;63(3):219-220. doi: 10.1055/a-2221-3220. Epub 2024 Jan 8.
9
Management of Dry Eye Toxicity After Treatment With Lu-PSMA-617 Radioligand Therapy.Lu-PSMA-617放射性配体治疗后干眼症毒性的管理。
Pract Radiat Oncol. 2024 Jul-Aug;14(4):301-304. doi: 10.1016/j.prro.2024.04.001. Epub 2024 Apr 16.
10
Evaluation of Lu and Sc Picaga-Linked, Prostate-Specific Membrane Antigen-Targeting Constructs for Their Radiotherapeutic Efficacy and Dosimetry.Lu 和 Sc 双载前列腺特异性膜抗原靶向构建物的放射治疗疗效和剂量学评价。
Mol Pharm. 2021 Dec 6;18(12):4511-4519. doi: 10.1021/acs.molpharmaceut.1c00711. Epub 2021 Oct 29.

引用本文的文献

1
MRI-Guided Adaptive Radiation Therapy for Oligometastatic Prostate Cancer Involving the Adrenal Gland: A Case Report and Literature Review.MRI引导下适形放疗用于肾上腺转移的寡转移前列腺癌：1例报告及文献综述
Case Rep Oncol. 2025 Apr 19;18(1):638-645. doi: 10.1159/000545983. eCollection 2025 Jan-Dec.

本文引用的文献

1
Isolated Adrenal Metastases of Castration-Resistant Prostate Cancer: Excellent Response to 177 Lu-PSMA With No Adrenal Insufficiency.去势抵抗性前列腺癌的孤立性肾上腺转移：对177镥-PSMA反应良好且无肾上腺功能不全
Clin Nucl Med. 2024 Jan 1;49(1):e8-e9. doi: 10.1097/RLU.0000000000004964. Epub 2023 Nov 22.
2
Joint EANM/SNMMI procedure guideline for the use of Lu-labeled PSMA-targeted radioligand-therapy (Lu-PSMA-RLT).EANM/SNMMI 联合实践指南：Lu 标记的 PSMA 靶向放射性配体治疗（Lu-PSMA-RLT）的应用。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830-2845. doi: 10.1007/s00259-023-06255-8. Epub 2023 May 29.
3
Complementary Role of 18 F-Fluciclovine PET/CT and 18 F-NaF PET/CT in Detecting Prostate Cancer Metastasis.
18F-氟柳氯维 PET/CT 和 18F-氟化钠 PET/CT 在检测前列腺癌转移中的互补作用。
Clin Nucl Med. 2023 Apr 1;48(4):330-331. doi: 10.1097/RLU.0000000000004583. Epub 2023 Jan 31.
4
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.美国食品药品监督管理局批准概要：镥 177 标记的维泊妥组单抗用于治疗转移性去势抵抗性前列腺癌患者。
Clin Cancer Res. 2023 May 1;29(9):1651-1657. doi: 10.1158/1078-0432.CCR-22-2875.
5
Unexpected Metastatic Localizations of Prostate Cancer Determined by Ga PSMA PET/CT: Series of Four Cases.镓 PSMA PET/CT 确定的前列腺癌意外转移部位：4 例系列报道
Mol Imaging Radionucl Ther. 2022 Oct 19;31(3):223-226. doi: 10.4274/mirt.galenos.2021.41033.
6
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones.前列腺癌肾上腺转移的特征：依赖于雄激素受体信号和类固醇激素。
Prostate Cancer Prostatic Dis. 2023 Dec;26(4):751-758. doi: 10.1038/s41391-022-00590-x. Epub 2022 Sep 13.
7
Potential Pitfall of Fluciclovine PET/CT in Castrate-Resistant Prostate Cancer With Adrenal Metastasis.氟脱氧葡萄糖 PET/CT 在去势抵抗性前列腺癌伴肾上腺转移中的潜在陷阱。
Clin Nucl Med. 2022 Dec 1;47(12):1061-1062. doi: 10.1097/RLU.0000000000004373. Epub 2022 Aug 26.
8
Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management.177Lu-PSMA放射性配体治疗后唾液腺功能评估：成像与管理的当前概念
Transl Oncol. 2022 Jul;21:101445. doi: 10.1016/j.tranon.2022.101445. Epub 2022 May 3.
9
Single Adrenal Metastasis From Prostate Cancer Detected by 68Ga-PSMA PET/CT and Confirmed by Biopsy: A Case Report.68Ga-PSMA PET/CT 发现并经活检证实的前列腺癌单发肾上腺转移：病例报告。
Clin Nucl Med. 2022 Jan 1;47(1):e61-e62. doi: 10.1097/RLU.0000000000003829.
10
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.